ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.04
-0.96 (-7.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.00
Open12.95
Bid11.37 x 1800
Ask13.01 x 800
Day's Range12.03 - 12.99
52 Week Range10.21 - 23.64
Volume258,081
Avg. Volume335,983
Market Cap660.939M
Beta (3Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-2.84
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.67
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 39th Annual Healthcare Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT

    Q4 2018 Intra-Cellular Therapies Inc Earnings Call

  • Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool26 days ago

    Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript

    ITCI earnings call for the period ending December 31, 2018.

  • GlobeNewswire26 days ago

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    NEW YORK, Feb. 27, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswirelast month

    Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswirelast month

    Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, February 27, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
    Investor's Business Dailylast month

    Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

    An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.

  • Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
    Simply Wall St.2 months ago

    Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • ACCESSWIRE3 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, NY / ACCESSWIRE / January 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • GlobeNewswire3 months ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)

    NEW YORK, Dec. 18, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies,.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease

    “We are disappointed for patients suffering from Alzheimer's disease that the interim analysis did not detect a signal that would warrant continuation of this study. Effective clinical study design is a challenge, especially for a therapeutic indication for which there are no approved treatments," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • Simply Wall St.3 months ago

    How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?

    Sharon Mates became the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2019. “The FDA’s acceptance of our NDA submission for lumateperone for the treatment of schizophrenia represents an important milestone and brings us closer to offering a potential advance in the treatment of patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT

    Q3 2018 Intra-Cellular Therapies Inc Earnings Call

  • Simply Wall St.5 months ago

    Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?

    If you own shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Associated Press5 months ago

    Intra-Cellular: 3Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 76 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire5 months ago

    Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2018. This portion of the study follows patients for up to 1-year of treatment with lumateperone after a switch from standard-of-care antipsychotic therapy.